Peptide Cheat Sheet 2026
Dosing, Reconstitution, Bloodwork & Nasal Sprays
Last updated: November 2026 | Author: BioChonch | For research and educational purposes only
What changed since the last version
- •In April 2026 the FDA took 12 peptides, including BPC-157 and TB-500, off its Category 2 compounding list. That is not approval: in July an FDA advisory committee recommended six of them, and the FDA still has to decide.
- •On 28 October 2026 HHS issued a draft policy: it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, TB-500, Epitalon, KPV, MOTS-c or Semax. Conditions apply, such as a single active ingredient per product. It is a draft, not an approval, and does not add them to the bulks list.
- •Retatrutide phase 3: in TRIUMPH-1 (NEJM, 2026), 12mg cut weight 25.0% at 80 weeks, counting everyone randomized; Lilly reports 28.3% for those who stayed on treatment. Dysesthesia (a burning skin sensation) affected 13% on 12mg vs 1% on placebo, per Lilly.
- •CagriSema phase 3: in REDEFINE 1 (NEJM, June 2025), cagrilintide 2.4mg plus semaglutide 2.4mg cut weight 20.4% at 68 weeks, counting everyone randomized.
- •KLOW corrected: it's the Glow Blend + KPV, not what was listed before
For research and educational purposes only. Not medical advice. Run bloodwork before any protocol.
How to use these tables
All tables assume a 1mL (100 unit) insulin syringe. If you're running a different vial size or BAC volume, use the BHG Reconstitution Calculator. Plug in your exact setup and it gives you the syringe units in 10 seconds.
🩹 1. Healing & Recovery
| Compound | Vial | BAC | Dose | Cycle | Bloodwork |
|---|---|---|---|---|---|
| BPC-157 | 10mg | 2mL | 500mcg daily | 8 wks | CBC, CRP, liver |
| |||||
| TB-500 | 10mg | 2mL | 3mg 2×/wk | 8 wks | CBC, CRP |
| |||||
| BPC/TB Blend | 20mg | 2mL | 500mcg ea daily | 8 wks | CBC, CRP, liver |
| |||||
| GHK-Cu | 50mg | 3mL | 1.7-2mg daily | 8 wks | Serum copper, liver |
| |||||
| KPV | 10mg | 2mL | 500mcg daily 5on/2off | 8 wks | CRP, CBC |
| |||||
| Thymosin α1 | 10mg | 2mL | 1.5mg 5on/2off | 8 wks | CBC diff, CD4/CD8, CRP |
| |||||
| Glow Blend | 70mg | 3mL | ~1.67mg daily | 8 wks | Serum copper, CBC |
| |||||
| KLOW Blend | 80mg | 3mL | ~1.67mg daily | 30 days | CBC, CRP, serum copper |
| |||||
Community nerve protocol: KLOW + CJC-1295/Ipamorelin daily for 2-3 weeks then maintenance, used for nerve repair and diabetic neuropathy. Community reports also describe using this combo for disc degeneration, nerve compression, and scoliosis-related pain. No published study has tested this combination for any of these.
🔥 2. Fat Loss & Metabolic
| Compound | Vial | BAC | Dose | Cycle | Bloodwork |
|---|---|---|---|---|---|
| Semaglutide | 30mg | 3mL | 250mcg-1mg weekly | 12-16 wks | Glucose, HbA1c, lipids, amylase/lipase |
| |||||
| Tirzepatide | 60mg | 6mL | 2.5-5mg weekly | 12-16 wks | Same as sema |
| |||||
| Retatrutide | 10mg | 3mL | 0.5-2mg weekly | 8-12 wks | Glucose, HbA1c, lipids |
| |||||
| Cagrilintide | 10mg | 2mL | 250mcg weekly | 8-12 wks | Same as GLP-1s |
| |||||
| Tesamorelin | 10mg | 2mL | 1mg daily 5on/2off | 8 wks | IGF-1, glucose, hs-CRP |
| |||||
| MOTS-c | 10mg | 2mL | 1mg daily 5on/2off | 8 wks | HbA1c, insulin, lipids |
| |||||
| 5-Amino-1MQ | 10mg | 2mL | 1mg daily 5on/2off | 8 wks | Glucose, insulin, liver |
| |||||
| Tesofensine | oral | — | 500mcg daily | 8-24 wks | HR, BP, glucose |
| |||||
| SLU-PP-332 | oral | — | 250mcg-1mg daily | 4-8 wks | Basic metabolic |
| |||||
| AOD-9604 | 5mg | 2mL | 250-500mcg daily | 8-12 wks | Basic metabolic |
| |||||
Cutting stack: Retatrutide + tesamorelin. In TRIUMPH-1, retatrutide 12mg weekly cut weight 25.0% at 80 weeks, counting everyone randomized. In two 26-week trials in adults with HIV and excess belly fat, tesamorelin 2mg daily cut visceral fat 15.4% more than placebo, with no significant change in belly fat under the skin. The doses in the table above are lower than in these trials. Semaglutide, tirzepatide and cagrilintide are also listed at or below their phase 3 doses: 2.4mg weekly in STEP 1, 5 to 15mg weekly in SURMOUNT-1 and 2.4mg weekly in REDEFINE 1. No trial has tested the pair, or whether tesamorelin protects muscle during GLP-1 weight loss. Full protocol with calculator: Ultimate Shred Stack
Protein on GLP-1s: A 2025 joint advisory from four US medical and nutrition societies notes targets of 1.2 to 1.6 g per kg a day proposed during weight loss, or a flat 80 to 120 g a day. It advises against 2 g per kg or more for long periods; 1 g per lb is 2.2 g per kg. It says more protein alone is unlikely to preserve muscle without resistance training.
💪 3. Growth Hormone & Recovery
| Compound | Vial | BAC | Dose | Cycle | Bloodwork |
|---|---|---|---|---|---|
| CJC/Ipa Blend | 10mg | 2mL | 250mcg ea PM | 8-12 wks | IGF-1, glucose |
| |||||
| Ipamorelin | 5mg | 2mL | 200-300mcg 1-2×/day | 8-12 wks | IGF-1, glucose |
| |||||
| Sermorelin | 5mg | 2mL | 200-300mcg nightly | 8-16 wks | IGF-1, glucose |
| |||||
| GHRP-2 | 5mg | 2mL | 100-300mcg 1-3×/day | 6-12 wks | IGF-1, prolactin, cortisol |
| |||||
| GHRP-6 | 5mg | 2mL | 100-300mcg 1-3×/day | 6-12 wks | IGF-1, prolactin, cortisol |
| |||||
| Hexarelin | 2mg | 2mL | 100-200mcg daily | 4-8 wks MAX | IGF-1, prolactin |
| |||||
| IGF-1 LR3 | 1mg | 1mL ACETIC | 50-200mcg pre workout | 10 days | IGF-1, glucose, kidney |
| |||||
| HGH Frag 176-191 | 5mg | 2mL | 250-500mcg daily | 4-8 wks | Basic metabolic |
| |||||
IGF-1 LR3 uses 0.6% acetic acid, NOT BAC water. It's the only exception in these tables. Repligen, which makes LONG R3 IGF-I, says to dissolve the powder in 100 mM acetic acid (about 0.6%) and that the product is not approved for any human use.
IGF-1 target: 200-300 ng/mL, never past 400. These are this sheet's working numbers, not a clinical range: normal IGF-1 falls with age, so compare with your lab's range for your age. Baseline + week 4 retest.
Pro tip: Pin CJC/Ipa fasted before bed, 2hr minimum after last meal. That timing is this sheet's rule; no trial has compared dosing times for these peptides. In 6 healthy adults, a glucose drink an hour earlier cut the GH peak from a GHRH injection by about 60%.
🧠 4. Cognitive & Mood
| Compound | Vial | BAC | Dose | Route | Cycle |
|---|---|---|---|---|---|
| Semax | 30mg | 3mL | 1mg 2-3×/wk | Intranasal | 8 wks |
| |||||
| Selank | 30mg | 3mL | 1mg 2-3×/wk | Intranasal | 8 wks |
| |||||
| Oxytocin | 5mg | 2mL | 16-40 IU PRN | Intranasal | PRN |
| |||||
| DSIP | 5mg | 2mL | 100-300mcg nightly | SubQ or intranasal | 2-4 wks |
| |||||
| Kisspeptin-10 | 5mg | 2mL | 50-100mcg 2-3×/wk | SubQ fasted | 4-8 wks |
| |||||
Russian Nootropic Stack: Semax in the morning, aimed at focus; Selank in the evening, aimed at calm. Both are sold in Russia as nasal drops. Russian stroke studies of Semax used 6 to 18mg a day; the table lists 1mg 2 to 3 times a week. No published study has given the two together or measured either peptide's levels in human blood, so whether nasal beats injection is unknown.
💨 5. Nasal Sprays (Intranasal, Pre-Mixed)
These come pre-mixed, no reconstitution needed. In rats, labeled Semax reached the brain within 2 minutes of a nasal dose.
| Compound | Format | Use Case |
|---|---|---|
| Selank 50mcg/spray | Atomized nasal spray | Anxiety / calm focus |
| Semax 100mcg/spray | Atomized nasal spray | Focus / cognition |
| PT-141 100mcg/spray | Atomized nasal spray | Libido / arousal |
| Oxytocin 100mcg/spray | Nasal spray | Bonding / social / mood |
| GABA + Melatonin + DSIP | Nasal spray blend | Sleep |
| Epitalon | Nasal spray | Longevity / sleep |
| Melanotan 2 | Nasal spray | Tanning |
| 5-Amino-1MQ | Nasal spray | Metabolic / energy |
Comparing nasal sprays? The nasal spray guide ranks 10 compounds by how well each suits the nasal route, weighing absorption, the evidence and the target.
Topical balms (no needles, no math)
| Compound | Product | Use Case |
|---|---|---|
| BPC-157 | No listed vendor | Recovery |
| GHK-Cu | No listed vendor | Skin / hair / collagen |
| Melanotan 2 | No listed vendor | Tanning |
🛡️ 6. Immune & Longevity
| Compound | Vial | BAC | Dose | Cycle | Bloodwork |
|---|---|---|---|---|---|
| Thymosin α1 | 10mg | 2mL | 1.5mg 5on/2off | 8 wks | CBC diff, CD4/CD8, CRP |
| |||||
| NAD+ | 500mg | 5mL | 50-100mg 2-3×/wk | 4-12 wks | CBC, CMP |
| |||||
| Epithalon | 10mg | 2mL | 5-10mg daily | 10-20 days 2-4×/yr | Optional telomere |
| |||||
| FOXO4-DRI | 10mg | 2mL | Research only | Experimental | CBC, CMP |
| |||||
| LL-37 | 5mg | 2mL | 100-250mcg daily | 2-6 wks | CBC, CRP, liver |
| |||||
💋 7. Sexual & Cosmetic
| Compound | Vial | BAC | Dose | Route | Bloodwork |
|---|---|---|---|---|---|
| PT-141 | 10mg | 2mL | 500mcg PRN | SubQ/intranasal | BP monitoring |
| |||||
| Melanotan 2 | 10mg | 2mL | 250mcg EOD loading | SubQ | BP + mole exam |
| |||||
| GHK-Cu | 50mg | 3mL | 1-2mg daily | SubQ or topical | Serum copper |
| |||||
| Enclomiphene | oral | — | 12.5-25mg daily | Oral | LH, FSH, T, E2, SHBG |
| |||||
MT-2 warning: Mole exam BEFORE starting. Any mole that changes shape, color or darkness: stop and see a derm.
🧪 8. Blends: Quick Reference
| Blend | Total | BAC | Dose | Use Case |
|---|---|---|---|---|
| Wolverine (BPC/TB) | 20mg | 2mL | 500mcg ea daily | Injury repair |
| ||||
| CJC/Ipa | 10mg | 2mL | 250mcg ea PM | Sleep + GH |
| ||||
| Glow | 70mg | 3mL | ~1.67mg daily | Skin + recovery |
| ||||
| KLOW | 80mg | 3mL | ~1.67mg daily | Repair + inflammation |
| ||||
KLOW = Glow + KPV. GHK-Cu + BPC-157 + TB-500 + KPV. No published study has tested this blend.
🧮 Reconstitution Rules
•Inject BAC slowly down the side of the vial. NEVER shake. Swirl gently.
•IGF-1 LR3 = 0.6% acetic acid only. Everything else uses BAC water.
•Storage: Dry powder in the freezer (-20 C); GenScript's handling guide says most dry peptides keep for several years there. Reconstituted in the fridge at 2 to 8 C, use within 28 days: common practice borrowed from the CDC rule for opened multi-dose vials, not a tested shelf life.
•GHK-Cu stings, users report. Use fatty areas, inject slowly.
•GH peptides fasted only: 2hr minimum after last meal.
Running a different vial size, BAC volume, or dose than the tables? Use the BHG Reconstitution Calculator. It handles any combination in 10 seconds.
🩸 Baseline Bloodwork Panel
Before any protocol:
Retest at week 4 for the relevant markers. If you're not measuring, you're guessing.
💬 Community Q&A
Can I stack multiple at once?
People do. The usual rule is to pick compounds on different pathways and not double up on one receptor. Apart from cagrilintide with semaglutide (CagriSema, above), none of the combinations on this page has been tested in a controlled trial in people. In the one controlled study of BPC-157 with TB-500 (32 rats), the pair did no better than either alone.
Nerve repair / diabetic neuropathy?
A community protocol: KLOW + CJC/Ipa daily 2-3 weeks then maintenance. No published study has tested this combination for nerve problems.
NAD frequency?
SubQ 2-3×/week. Oral NMN daily. IV session-based.
SLU-PP-332 dosing?
250mcg-1mg oral daily. It activates estrogen-related receptors (ERRs) and acted as an exercise mimetic in mice; its developers report that it lacks oral bioavailability. No study has given it to people.
Cutting stack?
Retatrutide + tesamorelin, a pair no trial has tested; the deep dive gives each drug's own trial data. Full deep dive here →
Disclaimer
For research and educational purposes only. Not medical advice. These are research chemicals and most are not FDA-approved for human use. Run bloodwork before and during any protocol. If you have any history of cancer, diabetes, cardiovascular disease, thyroid issues, pregnancy, or autoimmune conditions consult a licensed clinician first. Do your own research. Your decisions your responsibility.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.
Founder of BodyHackGuide. Writes the site's guides on peptide research, nootropics and vendor quality, and posts as u/BioChonch on Reddit.
This guide is for educational purposes only. Not medical advice. Always consult a healthcare professional.